Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screening

• 来源期刊: 亚洲男性学杂志（英文版）
• 年，卷（期）: 2011,（4）
• 页码范围: 614-615
• 页数: 2页
• 语种: 英文
• DOI: 10.1038/aja.2011.38

摘要

Determining the need for prostate biopsy remains one of the most controversial questions in urology.Over the past 10 years, practice guidelines have changed dramatically, especially among asymptomatic men with low prostate-specific antigen (PSA) and negative digital rectal exam.Thompson et al.Found that nearly 15% of men with PSA ＜4.0 had evidence of prostate cancer on biopsy;1 however, the clinical significance of these tumors is unclear.PSAvelocity (PSAV) has been suggested as a measurement to discriminate between aggressive and indolent cancers.Both the NCCN2 and AUA3 guidelines recommend considering prostate biopsy for men with PSA ＜4.0 and high PSAV (0.35 and 0.4 ng/ml/year, respectively); however, a recent article by Vickers et al.4 has called these recommendations into question, suggesting that PSAV adds little predictive accuracy to the standard risk factor assessment for prostate cancer.